Oxybutynin Chloride Extended Release

OXYBUTYNIN CHLORIDE

Manufacturer: AvPAK

Score: 145.0

Quick Summary

Oxybutynin Chloride Extended Release is a muscarinic antagonist used to treat overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. It is also used in pediatric patients aged 6 years and older with symptoms of detrusor overactivity associated with a neurological condition. The drug has a once-daily dosing regimen and is available in 5, 10, and 15 mg tablets. Important safety considerations include contraindications in patients with urinary retention, gastric retention, and uncontrolled narrow-angle glaucoma, as well as potential adverse reactions such as dry mouth, constipation, and dizziness.

Key Clinical Findings and Indications

Overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency
Detrusor overactivity associated with a neurological condition in pediatric patients aged 6 years and older

Important Safety Information

Warning

Oxybutynin Chloride Extended Release is contraindicated in patients with urinary retention, gastric retention, and uncontrolled narrow-angle glaucoma

Contraindications

Urinary retention
Gastric retention
Uncontrolled narrow-angle glaucoma
Known hypersensitivity to the drug substance or other components of the product

Adverse Reactions

Dry mouth
Constipation
Diarrhea
Headache
Somnolence
Dizziness

Dosing Recommendations

General Guidance

Dosage may be adjusted in 5-mg increments to achieve a balance of efficacy and tolerability

Overactive bladder

Adult Dose

5 or 10 mg once daily, with a maximum dose of 30 mg/day

Pediatric Dose

5 mg once daily, with a maximum dose of 20 mg/day

Special Population Considerations

Pregnancy

Oxybutynin Chloride Extended Release should be used during pregnancy only if the potential benefit to the patient outweighs the risk to the patient and fetus

Nursing Mothers

Caution should be exercised when Oxybutynin Chloride Extended Release is administered to a nursing woman

Pediatric Use

Oxybutynin Chloride Extended Release is not recommended in pediatric patients who cannot swallow the tablet whole without chewing, dividing, or crushing, or in children under the age of 6